Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic
Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are excluded. Successful implementation in public healthcare hinges on accurate estimates of eligibility rates in settings which will be the first to roll...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-03-01
|
| Seri Bilgileri: | The Journal of Prevention of Alzheimer's Disease |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2274580725004170 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|